BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28961369)

  • 1. Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.
    Wiredja DD; Ayati M; Mazhar S; Sangodkar J; Maxwell S; Schlatzer D; Narla G; Koyutürk M; Chance MR
    Proteomics; 2017 Nov; 17(22):. PubMed ID: 28961369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
    Schweppe DK; Rigas JR; Gerber SA
    J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
    J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
    Wang H; Xu K; Wang B; Liu J; Wang X; Xing M; Huang P; Guo Z; Xu L
    Environ Toxicol; 2017 Mar; 32(3):1065-1078. PubMed ID: 27352821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas.
    Sudhir PR; Hsu CL; Wang MJ; Wang YT; Chen YJ; Sung TY; Hsu WL; Yang UC; Chen JY
    PLoS One; 2011; 6(5):e20199. PubMed ID: 21637843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
    Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
    Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.
    Ståhl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtiö J
    J Proteome Res; 2011 May; 10(5):2566-78. PubMed ID: 21413766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.
    Coles GL; Cristea S; Webber JT; Levin RS; Moss SM; He A; Sangodkar J; Hwang YC; Arand J; Drainas AP; Mooney NA; Demeter J; Spradlin JN; Mauch B; Le V; Shue YT; Ko JH; Lee MC; Kong C; Nomura DK; Ohlmeyer M; Swaney DL; Krogan NJ; Jackson PK; Narla G; Gordan JD; Shokat KM; Sage J
    Cancer Cell; 2020 Jul; 38(1):129-143.e7. PubMed ID: 32531271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
    Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
    Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs.
    Kubiniok P; Finicle BT; Piffaretti F; McCracken AN; Perryman M; Hanessian S; Edinger AL; Thibault P
    Mol Cell Proteomics; 2019 Mar; 18(3):408-422. PubMed ID: 30482847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis.
    Ishii Y; Kuroda K; Matsushita K; Yokoo Y; Takasu S; Kijima A; Nohmi T; Ogawa K; Umemura T
    Toxicol Appl Pharmacol; 2017 Dec; 336():75-83. PubMed ID: 29054680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke.
    Babu N; Advani J; Solanki HS; Patel K; Jain A; Khan AA; Radhakrishnan A; Sahasrabuddhe NA; Mathur PP; Nair B; Keshava Prasad TS; Chang X; Sidransky D; Gowda H; Chatterjee A
    Microrna; 2018; 7(1):38-53. PubMed ID: 29299995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
    Arribas RL; Bordas A; Domènech Omella J; Cedillo JL; Janssens V; Montiel C; de Los Ríos C
    Bioorg Chem; 2020 Jul; 100():103874. PubMed ID: 32361056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial membrane protein 2 regulates sphingosylphosphorylcholine-induced keratin 8 phosphorylation and reorganization: Changes of PP2A expression by interaction with alpha4 and caveolin-1 in lung cancer cells.
    Lee EJ; Park MK; Kim HJ; Kim EJ; Kang GJ; Byun HJ; Lee CH
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1157-69. PubMed ID: 26876307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.